A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

Study Status

Open to Enrollment

Study Description

The purpose of this clinical trial is to determine if an investigational drug called LY2874544 can help patients with myeloproliferative neoplasms (MPNs). The study will also help determine the safety of LY2874544 and any side effects that might be associated with it.

LY2874544 inhibits a mutant protein that is found in a majority of non-chronic myeloid leukemia MPN patients. Inhibiting this mutant protein may bring about a better response in patients with MPN.

All patients in the study will receive LY2874544. The drug is taken orally once a day. The dose a patient receives will depend on the cohort that is open for enrollment when the patient has been determined to be eligible.

Patients will be in the study for approximately 30 weeks. Patients may stay on the study as long as they are benefiting from the study drug.

Disease Status and/or Stage

Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Myelofibrosis (MF)


Ely Lilly

Key Eligibility

  • Diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF)
    • PV: have failed or is unable to tolerate standard therapies
    • ET: have failed or is unable to tolerate standard therapies
    • MF: must meet one of the following:
      • Have intermediate 1, intermediate 2 or high-risk MF
      • Have symptomatic MF
      • Have post-polycythemic MF
      • Have post-ET MF
  • Men and women age 18 or older
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Ellen Ritchie, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page